The firm, based in Nantes, France, provides cell lines and media for the manufacture of vaccines and protein based drugs, as well as developing its own vaccine products in-house.
In a joint statement, CEO Franck Grimaud and CSO Majid Mehtali, said they were pleased with Vivalis new listing status on the NYSE Euronext indices, particularly as it follows just two years after the firm’s initial public offering (IPO).
The listing is likely to improve Vivalis' visibility, which if predictions about the growth of the biomanufacturing sector prove correct, can only help the firm in the long run.